Document is current
Any future updates will be listed below
-
Authors
Hosseini, Mohsen https://orcid.org/0000-0002-1686-8512
Voisin, Veronique https://orcid.org/0000-0002-3405-9532
Chegini, Ali https://orcid.org/0009-0007-8249-7258
Varesi, Angelica
Cathelin, Severine
Ayyathan, Dhanoop Manikoth
Liu, Alex C. H.
Yang, Yitong
Wang, Vivian
Maher, Abdula https://orcid.org/0009-0009-6535-6888
Grignano, Eric
Reisz, Julie A.
D’Alessandro, Angelo https://orcid.org/0000-0002-2258-6490
Young, Kira
Wu, Yiyan
Fiumara, Martina https://orcid.org/0009-0007-5934-9273
Ferrari, Samuele https://orcid.org/0000-0003-1122-1231
Naldini, Luigi https://orcid.org/0000-0002-7835-527X
Gaiti, Federico https://orcid.org/0000-0001-5111-8816
Pai, Shraddha
Egan, Grace https://orcid.org/0000-0002-4036-8403
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
Bader, Gary D.
Dick, John E.
Xie, Stephanie Z. https://orcid.org/0000-0002-0284-494X
Trowbridge, Jennifer J. https://orcid.org/0000-0002-7636-9504
Chan, Steven M. https://orcid.org/0000-0002-4354-0731
- License Information
-
More Information
Article History
Received: 18 January 2024
Accepted: 5 March 2025
First Online: 16 April 2025
Competing interests
: S.M.C. has received research funding from the Centre for Oncology and Immunology in Hong Kong, Celgene/BMS, AbbVie Pharmaceuticals, Agios Pharmaceuticals and Servier Laboratories. F.G. serves as a consultant for S2 Genomics Inc. A.D.S. has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz and Otsuka Pharmaceuticals. A.D.S. is named on a patent application for the use of DNT cells to treat AML. A.D.S. is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada. A.D.S. holds the Ronald N. Buick Chair in Oncology Research. J.E.D. has received research funding from Celgene/BMS, and has patents licensed to Trillium Therapeutics/Pfizer. J.J.T. has received research funding from H3 Biomedicine, Inc. and patent royalties from Fate Therapeutics. The other authors declare no competing interests.
